TISIDB

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell surface
Domain	PF00089 Trypsin
Function	Serine protease with trypsin- and chymotrypsin-like specificity. Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, antibacterial activity is inhibited by LPS from P.aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride.

> Gene Ontology [ TOP ]
Biological Process	GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001990 regulation of systemic arterial blood pressure by hormone GO:0001991 regulation of systemic arterial blood pressure by circulatory renin-angiotensin GO:0002002 regulation of angiotensin levels in blood GO:0002003 angiotensin maturation GO:0002237 response to molecule of bacterial origin GO:0002443 leukocyte mediated immunity GO:0002444 myeloid leukocyte mediated immunity GO:0002446 neutrophil mediated immunity GO:0003013 circulatory system process GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal GO:0003073 regulation of systemic arterial blood pressure GO:0003081 regulation of systemic arterial blood pressure by renin-angiotensin GO:0008015 blood circulation GO:0008217 regulation of blood pressure GO:0009620 response to fungus GO:0010817 regulation of hormone levels GO:0016485 protein processing GO:0016486 peptide hormone processing GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0031640 killing of cells of other organism GO:0032496 response to lipopolysaccharide GO:0035821 modification of morphology or physiology of other organism GO:0042445 hormone metabolic process GO:0042742 defense response to bacterium GO:0043062 extracellular structure organization GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044110 growth involved in symbiotic interaction GO:0044116 growth of symbiont involved in interaction with host GO:0044117 growth of symbiont in host GO:0044126 regulation of growth of symbiont in host GO:0044130 negative regulation of growth of symbiont in host GO:0044144 modulation of growth of symbiont involved in interaction with host GO:0044146 negative regulation of growth of symbiont involved in interaction with host GO:0044364 disruption of cells of other organism GO:0045926 negative regulation of growth GO:0050830 defense response to Gram-positive bacterium GO:0050832 defense response to fungus GO:0050886 endocrine process GO:0051604 protein maturation GO:0051702 interaction with symbiont GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction GO:0051818 disruption of cells of other organism involved in symbiotic interaction GO:0051851 modification by host of symbiont morphology or physiology GO:0051852 disruption by host of symbiont cells GO:0051873 killing by host of symbiont cells GO:0051883 killing of cells in other organism involved in symbiotic interaction GO:0060177 regulation of angiotensin metabolic process GO:0070942 neutrophil mediated cytotoxicity GO:0070943 neutrophil mediated killing of symbiont cell GO:0070944 neutrophil mediated killing of bacterium GO:0070946 neutrophil mediated killing of gram-positive bacterium GO:0098542 defense response to other organism
Molecular Function	GO:0004175 endopeptidase activity GO:0004252 serine-type endopeptidase activity GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0008236 serine-type peptidase activity GO:0017171 serine hydrolase activity GO:1901681 sulfur compound binding
Cellular Component	GO:0030141 secretory granule GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04080 Neuroactive ligand-receptor interaction hsa04142 Lysosome hsa04614 Renin-angiotensin system
Reactome	R-HSA-1592389: Activation of Matrix Metalloproteinases R-HSA-6803157: Antimicrobial peptides R-HSA-1474228: Degradation of the extracellular matrix R-HSA-1474244: Extracellular matrix organization R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-2022377: Metabolism of Angiotensinogen to Angiotensins R-HSA-392499: Metabolism of proteins R-HSA-6798695: Neutrophil degranulation R-HSA-2980736: Peptide hormone metabolism R-HSA-381426: Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04080 Neuroactive ligand-receptor interaction
hsa04142 Lysosome
hsa04614 Renin-angiotensin system

Reactome

R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-6803157: Antimicrobial peptides
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-2022377: Metabolism of Angiotensinogen to Angiotensins
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-2980736: Peptide hormone metabolism
R-HSA-381426: Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CTSG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CTSG and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23147993	Acute Myeloid Leukemia	Promote immunity	We showed killing of primary AML by CG1-CTL, but not normal bone marrow. Blocking HLA-A0201 abrogated CG1-CTL-mediated cytotoxicity, further confirming HLA-A0201-dependent killing. Finally, we showed functional CG1-CTLs in peripheral blood from AML patients following allogeneic stem cell transplantation. CG is aberrantly expressed and processed in AML and is a novel immunotherapeutic target that warrants further development.

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CTSG in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CTSG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.736	0.334
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.399	0.771
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.95	0.323
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.025	0.975
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.491	0.742
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.692	0.652
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.048	0.963
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.414	0.783
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.572	0.718
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.134	0.241
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.376	0.0484
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.628	0.0475

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CTSG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	7.4	-7.4	0.169
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTSG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTSG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTSG. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTSG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CTSG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CTSG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CTSG
Name	cathepsin G
Aliases	CG; CATG
Chromosomal Location	14q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CTSG collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CTSG.

ID	Name	Drug Type	Targets	#Targets
DB02360	Bis-Napthyl Beta-Ketophosphonic Acid	Small Molecule	CTSG	1
DB04016	2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid	Small Molecule	CMA1, CTSG	2

Browse CTSG